-
For patients with advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplatin does not improve progression-free survival or overall survival.
-
The mechanism for a possible adverse effect of hormone therapy on the biliary system is believed to be estrogen-induced increases in cholesterol saturation in the bile and progestin inhibition of gallbladder contraction, leading to gallstone formation.
-
The SGO and ACOG referral guidelines effectively separate women with pelvic masses into 2 risk categories for malignancy. This distinction permits a rational approach for referring high-risk patients to a gynecologic oncologist for management.
-
-
-
Diluigi and colleagues in Rhode Island compared the outcomes of 400 patients undergoing hysterectomy with 686 hysterectomy cases performed prior to the institution of a policy for prophylactic antibiotics. Abdominal, vaginal, and laparoscopic cases were included, with the primary aspects being rates and timing of preoperative antibiotic administration as well as postoperative febrile morbidity.
-
In some hospitals Vaginal Birth After Cesarean (VBAC) has been eliminated as an option for patients having had previous Cesarean sections. Although the major reason stated for this position has been risk of uterine rupture, there is more to this stance which involves potential liability and the inconvenience to providers of having to be immediately available for the duration of these patients labors.
-
The effect of caloric restriction upon metabolism was gated by whether sugars or fats were preferentially restricted. A low-glycemic load diet (glucose restriction) yielded more favorable biochemical profiles than restricting fats.
-
Consolidation therapy with oregovomab did not significantly improve TTR overall. A set of confirmatory phase III studies has been initiated to determine whether the SFLT population derives benefit from oregovomab treatment.
-
Womens Health Initiative (WHI) investigators from Wayne State University performed an analysis using the WHI database and presented the results at the 2004 annual meeting of the American Society of Reproductive Medicine (ASRM). Two months later, the presentation on the effects of oral contraception on cardiovascular disease drew a critical response from the director of the WHI, Barbara Alving, MD, who is also the acting director of the National Heart, Lung, and Blood Institute.
